Vaccination with LAG-3Ig (IMP321) and peptides induces specific CD4 and CD8 T-cell responses in metastatic melanoma patients-report of a phase I/IIa clinical trial

Clinical Cancer Research

Volumn 22, Issue 6, 2016, Pages 1330-1340

  Legat, Amandine ^a   Maby El Hajjami, Hélène ^a   Baumgaertner, Petra ^a   Cagnon, Laurène ^a,b   Maillard, Samia Abed ^a,b   Geldhof, Christine ^a   Iancu, Emanuela M ^b   Lebon, Luc ^a   Guillaume, Philippe ^c   Dojcinovic, Danijel ^c   Michielin, Olivier ^b   Romano, Emanuela ^b   Berthod, Grégoire ^b   Rimoldi, Donata ^a   Triebel, Frédéric ^d   Luescher, Immanuel ^c   Rufer, Nathalie ^a,b   Speiser, Daniel E ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c SA ^*  (Switzerland)

^d Immutep   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; INTERLEUKIN 2; MAGE A3 112-120 MAGE A3 243-258 MELAN A 26-35 NA17 NY ESO 1 157-165 LAG 3IG MONTANIDE ISA 51 VACCINE; MELAN A; MELANOMA ANTIGEN 3; MONTANIDE ISA 51; NY ESO 1 ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CD223 ANTIGEN; LEUKOCYTE ANTIGEN; PEPTIDE; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SAFETY; DRUG TOLERABILITY; EX VIVO STUDY; FEMALE; HEADACHE; HUMAN; HUMAN CELL; IN VITRO STUDY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE REACTIVATION; INJECTION SITE ULCER; INJECTION SITE WARMTH; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STAINING; SYSTEMIC DISEASE; VACCINATION REACTION; CHEMISTRY; CLINICAL TRIAL; IMMUNOLOGY; MELANOMA; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TREATMENT OUTCOME; VACCINATION;

ANTIGENS, CD; ANTIGENS, NEOPLASM; BIOMARKERS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHOCYTE COUNT; MALE; MART-1 ANTIGEN; MELANOMA; PEPTIDES; TREATMENT OUTCOME; VACCINATION;

EID: 84962326872     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1212     Document Type: Article

References (49)

1. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma.NEngl J Med 2004;351:998-1012.
2. Sznol M. Molecular markers of response to treatment for melanoma. Cancer J 2011;17:127-33.
3. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutantmelanoma. Nature 2010;467:596-9.
4. Petrella T,Quirt I, Verma S,Haynes AE, Charette M, BakK, et al. Single-agent interleukin-2 in the treatment of metastatic melanoma. Curr Oncol 2007;14:21-6.
5. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J MedN Engl J Med 2010;363:711-23.
6. Curti BD, Urba WJ. Clinical deployment of antibodies for treatment of melanoma. Mol Immunol 2015;67:18-27.
7. Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer 2014;111:2214-9.
8. Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol 2015;33C:23-35.
9. Sierro S, Romero P, Speiser DE. The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets 2011;15:91-101.
10. Makkouk A, Weiner GJ. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res 2015;75: 5-10.
11. Brubaker SW, Bonham KS, Zanoni I, Kagan JC. Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol 2015;33: 257-90.
12. Fougeray S, Brignone C, Triebel F. A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: Preclinical evaluation of IMP321. Vaccine 2006;24:5426-33.
13. Brignone C, Grygar C, Marcu M, Schakel K, Triebel F. A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol 2007;179:4202-11.
14. Brignone C, Grygar C, Marcu M, Perrin G, Triebel F. IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Imm Based Ther Vacc 2007;5:5-20.
15. Brignone C, Grygar C, Marcu M, Perrin G, Triebel F. IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: a single-blind phase I study. Vaccine 2007;25:4641-50.
16. Brignone C, Escudier B, Grygar C, Marcu M, Triebel F. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 2009;15:6225-31.
17. Brignone C, Gutierrez M, Mefti F, Brain E, Jarcau R, Cvitkovic F, et al. Firstline chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Translat Med 2010;8:71.
18. Romano E, Michielin O, Voelter V, Laurent J, Bichat H, Stravodimou A, et al. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J Translat Med 2014;12:97.
19. Pittet MJ, Zippelius A, Speiser DE, Assenmacher M, Guillaume P, Valmori D, et al. Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol 2001;166:7634-40.
20. Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A 2007;104:8947-52.
21. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006;24:175-208.
22. Ayyoub M, Zippelius A, PittetMJ, Rimoldi D, ValmoriD, Cerottini JC, et al. Activation of humanmelanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin Cancer Res 2003;9:669-77.
23. Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, Hammann-Haenni A, et al. Nano-particle vaccination combinedwith TLR- 7 and -9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients. Eur J Immunol 2012;42:3049-61.
24. Lienard D, Rimoldi D, Marchand M, Dietrich PY, van Baren N, Geldhof C, et al. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun 2004;4:4-23.
25. Lesimple T, Neidhard EM, Vignard V, Lefeuvre C, Adamski H, Labarriere N, et al. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin Cancer Res 2006;12:7380-8.
26. Slingluff CLJ. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J 2011;17: 343-50.
27. Speiser DE, Romero P. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin Immun 2010;22: 144-54.
28. Iancu EM, Gannon PO, Laurent J, Gupta B, Romero P,Michielin O, et al. Persistence of EBV antigen-specific CD8 T cell clonotypes during homeostatic immune reconstitution in cancer patients. PloS One 2013;8:e78686.
29. Hadrup SR, Bakker AH, Shu CJ, Andersen RS, van Veluw J, Hombrink P, et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 2009;6: 520-6.
30. Newell EW, Klein LO, YuW,DavisMM. Simultaneous detection ofmany Tcell specificities using combinatorial tetramer staining. Nat Methods 2009;6:497-9.
31. Bordry N, Costa-Nunes CM, Cagnon L, Gannon PO, Abed-Maillard S, Baumgaertner P, et al. Pulmonary sarcoid-like granulomatosis after multiple vaccinations of a long-term surviving patient with metastatic melanoma. Cancer Immunol Res 2014;2:1148-53.
32. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005;115: 739-46.
33. Schultz ES, Lethe B, Cambiaso CL, VanSnick J, Chaux P, Corthals J, et al. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4 +cytolytic T lymphocytes. Cancer Res 2000;60:6272-5.
34. Schultz ES, Schuler-Thurner B, Stroobant V, Jenne L, Berger TG, Thielemanns K, et al. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-basedimmunotherapy. J Immunol 2004;172:1304-10.
35. Hebeisen M, Oberle SG, Presotto D, Speiser DE, Zehn D, Rufer N. Molecular insights for optimizing T cell receptor specificity against cancer. Front Immunol 2013;4:154.
36. Stone JD, Chervin AS, Kranz DM. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology 2009;126: 165-76.
37. Powell DJ, Jr., Rosenberg SA. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. J Immunother 2004;27:36-47.
38. Slingluff CL, Petroni GR, Smolkin ME, Chianese-Bullock KA, Smith K, Murphy C, et al. Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines. J Immunother 2010;33:630-8.
39. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003;300:337-9.
40. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003;421:852-6.
41. Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, et al. Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 2009;206:849-66.
42. Ayyoub M, Dojcinovic D, Pignon P, Raimbaud I, Schmidt J, Luescher I, et al. Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHCclass II/His-tag-peptide tetramers. Proc Natl Acad SciUS A 2010;107: 7437-42.
43. Bankovich AJ, Girvin AT, Moesta AK, Garcia KC. Peptide register shifting within the MHC groove: theory becomes reality. Mol Immunol 2004;40: 1033-9.
44. Cecconi V, Moro M, Del Mare S, Sidney J, Bachi A, Longhi R, et al. The CD4 +T-cell epitope-binding register is a critical parameter when generating functional HLA-DR tetramers with promiscuous peptides. Eur J Immunol 2010;40:1603-16.
45. Landais E, Romagnoli PA, Corper AL, Shires J, Altman JD, Wilson IA, et al. New design of MHC class II tetramers to accommodate fundamental principles of antigen presentation. J Immunol 2009;183:7949-57.
46. Lienard D, Avril MF, Le Gal FA, Baumgaertner P, Vermeulen W, Blom A, et al. Vaccination ofmelanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant. J Immunother 2009;32:875-83.
47. Pulendran B, Oh JZ, Nakaya HI, Ravindran R, Kazmin DA. Immunity to viruses: learning from successful human vaccines. Immunol Rev 2013; 255:243-55.
48. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69-74.
49. Verdeil G, Fuertes Marraco SA, Murray T, Speiser DE. From T cell "exhaustion" to anti-cancer immunity. BiochimBiophys Acta 2015. doi: 10.1016/j.bbcan.2015.06.007.